Boston Common Asset Management LLC Has $14.40 Million Holdings in Gilead Sciences, Inc. $GILD

Boston Common Asset Management LLC grew its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 6.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 129,689 shares of the biopharmaceutical company’s stock after acquiring an additional 7,604 shares during the period. Boston Common Asset Management LLC’s holdings in Gilead Sciences were worth $14,395,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also modified their holdings of GILD. Brighton Jones LLC raised its position in shares of Gilead Sciences by 20.6% during the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock worth $1,326,000 after acquiring an additional 2,450 shares during the last quarter. Bison Wealth LLC acquired a new stake in Gilead Sciences in the fourth quarter worth about $215,000. Sivia Capital Partners LLC increased its position in Gilead Sciences by 16.8% in the second quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock worth $464,000 after purchasing an additional 602 shares during the period. CHICAGO TRUST Co NA lifted its position in Gilead Sciences by 25.9% during the 2nd quarter. CHICAGO TRUST Co NA now owns 2,900 shares of the biopharmaceutical company’s stock valued at $322,000 after purchasing an additional 597 shares during the period. Finally, Waycross Partners LLC bought a new position in shares of Gilead Sciences in the 2nd quarter valued at about $636,000. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Stock Performance

Shares of GILD opened at $129.11 on Thursday. The firm has a market cap of $160.18 billion, a P/E ratio of 20.02, a PEG ratio of 0.65 and a beta of 0.33. Gilead Sciences, Inc. has a twelve month low of $91.84 and a twelve month high of $129.39. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45. The firm’s 50 day moving average price is $123.64 and its two-hundred day moving average price is $118.37.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. The business had revenue of $7.77 billion for the quarter, compared to analyst estimates of $7.42 billion. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The firm’s quarterly revenue was up 3.0% on a year-over-year basis. During the same period last year, the business posted $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th were issued a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date was Monday, December 15th. Gilead Sciences’s payout ratio is 48.99%.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $122.00, for a total transaction of $366,000.00. Following the completion of the transaction, the chief financial officer owned 153,503 shares of the company’s stock, valued at $18,727,366. This represents a 1.92% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Johanna Mercier sold 28,000 shares of the firm’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $125.86, for a total transaction of $3,524,080.00. Following the transaction, the insider directly owned 107,193 shares of the company’s stock, valued at $13,491,310.98. This represents a 20.71% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 141,757 shares of company stock valued at $17,569,112 over the last ninety days. Company insiders own 0.27% of the company’s stock.

Key Stories Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: NEJM published full Phase 3 ASCENT-04/KEYNOTE-D19 results showing Trodelvy® (sacituzumab govitecan) + Keytruda® met the primary endpoint with a 35% PFS improvement (HR 0.65), supporting the combination as a potential new first-line standard in PD-L1+ metastatic TNBC — a meaningful commercial upside for Gilead’s Trodelvy franchise. New England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results
• Positive Sentiment: Rothschild & Co Redburn raised its GILD price target to $159 and kept a “buy” rating, signaling institutional confidence and providing upside thesis support to momentum traders and fundamental buyers. Rothschild & Co Redburn Adjusts Price Target on Gilead Sciences
• Positive Sentiment: Investor commentary highlights margin expansion and stronger free cash flow as underappreciated drivers for Gilead’s valuation, supporting buy-side interest beyond the clinical story. Gilead Sciences: Margin Expansion And Cash Flow Strength Underpriced
• Neutral Sentiment: Market commentary includes a valuation check after recent share-price softness — useful context for investors assessing whether the recent run is a buy-the-news move or a reset toward fair value. Gilead Sciences (GILD) Valuation Check After Recent Share Price Softness
• Neutral Sentiment: Technical/relative-strength pieces note improved momentum in GILD, which can attract momentum traders but doesn’t change fundamentals by itself. Stocks generating improved relative strength: Gilead Sciences
• Negative Sentiment: Director Jeffrey Bluestone sold 5,000 shares (~$617.5k at $123.50) and reduced his stake by ~35.9% — an insider sale that may prompt investor questions about timing or tax/liquidity motives. SEC Filing — Form 4
• Negative Sentiment: RBC raised its target slightly to $103 but kept a “sector perform” rating — that target sits well below current levels and represents a cautious analyst view that could cap upside if other brokers follow suit. RBC Lifts Price Target on Gilead Sciences to $103

Analysts Set New Price Targets

A number of research firms recently weighed in on GILD. Daiwa Capital Markets boosted their price target on shares of Gilead Sciences from $128.00 to $129.00 and gave the stock an “outperform” rating in a research note on Thursday, November 13th. JPMorgan Chase & Co. upped their target price on shares of Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a research report on Friday, October 31st. Sanford C. Bernstein set a $135.00 price target on Gilead Sciences and gave the stock an “outperform” rating in a research report on Monday, December 29th. The Goldman Sachs Group upped their price objective on Gilead Sciences from $110.00 to $115.00 and gave the company a “neutral” rating in a report on Thursday, January 8th. Finally, Rothschild & Co Redburn boosted their target price on Gilead Sciences from $153.00 to $159.00 and gave the stock a “buy” rating in a research report on Tuesday. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $133.52.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.